Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesCurrent and emerging strategies for the prevention of graft-versus-host diseaseAcute graft-versus-host disease: a bench-to-bedside update.Current and future approaches for control of graft-versus-host disease.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrRituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantationAllogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidencePhase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Prevention of graft-vs.-host diseaseApproaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationAcute graft-versus-host disease: new treatment strategies.The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.Rituximab in hematopoietic cell transplantation.Progress and prospects: graft-versus-host disease.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?Accelerated therapeutic progress in diffuse large B cell lymphoma.Recent advances on cellular therapies and immune modulators for graft-versus-host disease.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation.Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
P2860
Q26745838-61518D62-B504-4694-9BAD-1710F8C5A630Q27016541-D6884F6A-4BC0-4053-84D3-6E9174A14529Q27687130-2F0A2308-022F-44FA-A440-26634AABBC2CQ33642625-B385D2A4-8C0B-4093-8B8C-5D0AA78F85ABQ34044024-4FF6D59D-4072-422A-9FA4-77A475DE2492Q34164140-41765291-BADF-491A-9A0C-C92F6C09B488Q34240410-D660504B-796A-4BE6-852F-9A80955753D3Q34860077-31D0A8DB-3274-44A0-B9CC-26722779F5E8Q35115650-F434ADE1-938B-4108-A81B-C74610BCA198Q35187185-26C4341A-E817-4896-9B84-8AF39F69C721Q35607308-E474F09C-5D0D-40CE-98C9-CDA50FFD4BC8Q36057911-0172115E-8B11-418A-A79C-2DC5151EC3BAQ36264895-3FBF0675-BB66-4FE8-BEAF-58A23D7395C5Q36431047-68BA8B84-CC1F-43E4-B9DE-37E2D74A0111Q36891433-744F115B-89B7-4353-A913-E1ADCE0D88AFQ37610714-7FD369E2-6EAD-4C62-9C07-62C9CEE6361AQ37689179-4C23DEC9-7B99-4FB9-AC8A-B159F44944AAQ37737311-BAAE819A-D8C8-4849-8D35-118FF942DF73Q37761297-67504955-97CC-4EC9-8B7D-E2510793F228Q37843939-26CEE7F1-E188-4DAE-925E-E623F183D203Q38066586-D6872827-C0EA-4054-A144-CB1D70538E99Q38074021-9C95DC6F-2246-4AE5-AD00-EB4AC6023DCAQ38115231-3AF2A011-0D8C-4A69-8C4E-680CA67F0B7EQ38174498-F30F76AB-B56A-4E48-BF68-0195B590D271Q38246755-CE154972-96F4-4513-B11F-BC4FF8054341Q38392246-5E9DB678-8B14-4B3E-B058-B6B27DE6AAD2Q38829335-83B861F0-3D79-40AD-86A7-508CC5B0A86CQ38918124-5187EB01-E129-4722-A054-118879592A9BQ40097140-7B511486-C2CC-4A39-8978-D1C81E8F9D14Q40892130-00BF5838-AD96-44B3-B9DE-C50E2EC67A71Q47142494-414AD960-1BC1-479D-B8B2-A8DA117108BFQ47431505-76EAF182-A758-4F80-9BA4-1BCC85BDF94DQ50225112-7CED66DC-31FA-4A21-8DE5-5B8875C25694Q52880975-AF04F3C4-ED9C-4A53-A7CD-751AB857A69CQ53297754-F7589CB7-65A7-4DB7-8465-E5CC8E013B5C
P2860
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Prior rituximab correlates wit ...... lood stem cell transplantation
@ast
Prior rituximab correlates wit ...... lood stem cell transplantation
@en
type
label
Prior rituximab correlates wit ...... lood stem cell transplantation
@ast
Prior rituximab correlates wit ...... lood stem cell transplantation
@en
prefLabel
Prior rituximab correlates wit ...... lood stem cell transplantation
@ast
Prior rituximab correlates wit ...... lood stem cell transplantation
@en
P2093
P2860
P1476
Prior rituximab correlates wit ...... lood stem cell transplantation
@en
P2093
Brent Logan
Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA
Corey Cutler
Gregory Hale
Hanna Khoury
Joseph Antin
Joseph P Uberti
Leo Verdonck
Martin Bornhaüser
P2860
P304
P356
10.1111/J.1365-2141.2009.07674.X
P407
P577
2009-03-26T00:00:00Z